Drugs / Obutinib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06683885 | Nov 2024 → May 2026 overdue | diffuse large B-cell lymphoma | Mingzhi Zhang | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06748521 | Dec 2024 → Dec 2026 expected | diffuse large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | obutinib | “treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.” NCT06748521 ↗ |
| Route | Oral | “Obutinib, 150mg, QD, P.O.” NCT06683885 ↗ |